FDA expert panel lines up 19-to-1 against Pfizer’s osteoarthritis drug tanezumab
Outside experts advising the FDA voted 19 to 1 against Pfizer’s potential osteoarthritis drug tanezumab, saying the proposed risk evaluation and mitigation strategy (REMS) will not ensure the benefits of the drug outweigh the risks. One of the two consumer reps voted yes.
Two different FDA advisory committees on arthritis and drug safety came together over the last day and a half to review Pfizer’s drug, with panelists raising serious concerns about the safety of the drug and how effective it is.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.